Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2007 3
2008 5
2009 4
2010 1
2011 3
2012 2
2015 3
2016 5
2017 2
2018 1
2020 2
2021 4
2022 4
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

37 results

Results by year

Filters applied: . Clear all
Page 1
Retraction: Acharya CR, et al. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer. JAMA. 2008;299(13):1574-1587.
Acharya CR, Hsu DS, Anders CK, Anguiano A, Salter KH, Walters KS, Redman RC, Tuchman SA, Moylan CA, Mukherjee S, Barry WT, Dressman HK, Ginsburg GS, Marcom KP, Garman KS, Lyman GH, Nevins JR, Potti A. Acharya CR, et al. JAMA. 2012 Feb 1;307(5):453. doi: 10.1001/jama.2012.2. Epub 2012 Jan 6. JAMA. 2012. PMID: 22228686 No abstract available.
Combination of a novel heat shock protein 90-targeted photodynamic therapy with PD-1/PD-L1 blockade induces potent systemic antitumor efficacy and abscopal effect against breast cancers.
Kaneko K, Acharya CR, Nagata H, Yang X, Hartman ZC, Hobeika A, Hughes PF, Haystead TAJ, Morse MA, Lyerly HK, Osada T. Kaneko K, et al. Among authors: acharya cr. J Immunother Cancer. 2022 Sep;10(9):e004793. doi: 10.1136/jitc-2022-004793. J Immunother Cancer. 2022. PMID: 36171008 Free PMC article.
HSP90-Specific nIR Probe Identifies Aggressive Prostate Cancers: Translation from Preclinical Models to a Human Phase I Study.
Osada T, Crosby EJ, Kaneko K, Snyder JC, Ginzel JD, Acharya CR, Yang XY, Polascik TJ, Spasojevic I, Nelson RC, Hobeika A, Hartman ZC, Neckers LM, Rogatko A, Hughes PF, Huang J, Morse MA, Haystead T, Lyerly HK. Osada T, et al. Among authors: acharya cr. Mol Cancer Ther. 2022 Jan;21(1):217-226. doi: 10.1158/1535-7163.MCT-21-0334. Epub 2021 Oct 21. Mol Cancer Ther. 2022. PMID: 34675120 Free PMC article. Clinical Trial.
Combination of ultrasound-based mechanical disruption of tumor with immune checkpoint blockade modifies tumor microenvironment and augments systemic antitumor immunity.
Abe S, Nagata H, Crosby EJ, Inoue Y, Kaneko K, Liu CX, Yang X, Wang T, Acharya CR, Agarwal P, Snyder J, Gwin W, Morse MA, Zhong P, Lyerly HK, Osada T. Abe S, et al. Among authors: acharya cr. J Immunother Cancer. 2022 Jan;10(1):e003717. doi: 10.1136/jitc-2021-003717. J Immunother Cancer. 2022. PMID: 35039461 Free PMC article.
HER2 Isoforms Uniquely Program Intratumor Heterogeneity and Predetermine Breast Cancer Trajectories During the Occult Tumorigenic Phase.
Ginzel JD, Acharya CR, Lubkov V, Mori H, Boone PG, Rochelle LK, Roberts WL, Everitt JI, Hartman ZC, Crosby EJ, Barak LS, Caron MG, Chen JQ, Hubbard NE, Cardiff RD, Borowsky AD, Lyerly HK, Snyder JC. Ginzel JD, et al. Among authors: acharya cr. Mol Cancer Res. 2021 Oct;19(10):1699-1711. doi: 10.1158/1541-7786.MCR-21-0215. Epub 2021 Jun 15. Mol Cancer Res. 2021. PMID: 34131071 Free PMC article.
Immune signatures predict prognosis in localized cancer.
Hsu DS, Kim MK, Balakumaran BS, Acharya CR, Anders CK, Clay T, Lyerly HK, Drake CG, Morse MA, Febbo PG. Hsu DS, et al. Among authors: acharya cr. Cancer Invest. 2010 Aug;28(7):765-73. doi: 10.3109/07357900903095755. Cancer Invest. 2010. PMID: 20569070 Free PMC article.
37 results